目的:2型糖尿病(T2DM)对等待肝移植(LT)的终末期肝病(ESLD)患者的影响尚不明确。本研究的目的是评估LT等待列表注册患者中T2DM与临床结局之间的关系。我们假设T2DM的存在将与更差的临床结果相关。
方法:在2010年1月1日至2017年1月1日期间登记接受LT的593例成人(18岁或以上)患者被纳入本回顾性分析。2型糖尿病对肝脏相关临床事件(LACE)的影响,生存,住院治疗,需要肾脏替代治疗,并在12个月内评估接受LT的可能性.LACE被定义为静脉曲张出血,肝性脑病,和腹水。使用Kaplan-Meier和Cox回归分析来确定T2DM与临床结局之间的关联。
结果:T2DM的基线患病率为32%(n=191),T2DM患者更容易发生食管静脉曲张(61%vs.47%,p=0.002)和静脉曲张出血病史(23%vs.16%,p=0.03)。2型糖尿病的存在与腹水的风险增加相关(HR1.91,95%CI1.11,3.28,p=0.019)。T2DM患者更有可能需要住院治疗(56%vs.49%,p=0.06),门脉高压相关并发症住院(22%vs.14%;p=0.026),住院期间需要肾脏替代治疗。T2DM患者接受LT的可能性较小(37%vs.45%;p=0.03)。关于MELD实验室,2型糖尿病患者在每次随访时胆红素均显著降低;然而,INR和肌酐无差异.
结论:T2DM患者的临床结局风险增加。此风险未记录在MELD评分中,这可能会对他们接受LT的可能性产生负面影响。
OBJECTIVE: Impact of type 2 diabetes mellitus (T2DM) in patients with end-stage liver disease (ESLD) awaiting liver transplantation (LT) remains poorly defined. The objective of the present study is to evaluate the relationship between T2DM and clinical outcomes among patients with LT waitlist registrants. We hypothesize that the presence of T2DM will be associated with worse clinical outcomes.
METHODS: 593 patients adult (age 18 years or older) who were registered for LT between 1/2010 and 1/2017 were included in this retrospective analysis. The impact of T2DM on liver-associated clinical events (LACE), survival, hospitalizations, need for renal replacement therapy, and likelihood of receiving LT were evaluated over a 12-month period. LACE was defined as variceal hemorrhage, hepatic encephalopathy, and ascites. Kaplan-Meier and Cox regression analysis were used to determine the association between T2DM and clinical outcomes.
RESULTS: The baseline prevalence of T2DM was 32% (n = 191) and patients with T2DM were more likely to have esophageal varices (61% vs. 47%, p = 0.002) and history of variceal hemorrhage (23% vs. 16%, p = 0.03). The presence of T2DM was associated with increased risk of incident ascites (HR 1.91, 95% CI 1.11, 3.28, p = 0.019). Patients with T2DM were more likely to require hospitalizations (56% vs. 49%, p = 0.06), hospitalized with portal hypertension-related complications (22% vs. 14%; p = 0.026), and require renal replacement therapy during their hospitalization. Patients with T2DM were less likely to receive a LT (37% vs. 45%; p = 0.03). Regarding MELD labs, patients with T2DM had significantly lower bilirubin at each follow-up; however, no differences in INR and creatinine were noted.
CONCLUSIONS: Patients with T2DM are at increased risk of clinical outcomes. This risk is not captured in MELD score, which may potentially negatively affect their likelihood of receiving LT.